This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Fingolimod (FTY720, Gilenya, Novartis Pharma AG, Basel, Switzerland) is an oral disease-modifying therapy (DMT) approved for relapsing multiple sclerosis (MS) that acts via modulation of the sphingosine-1-phosphate (S1P) receptor.1 Fingolimod also targets the cardiovascular system, frequently causing reduced heart rate after the first dose.2 We describe a patient with MS who developed paroxysmal atrial fibrillation (PAF) after initiating fingolimod therapy.
Footnotes
Author contributions: Primary patient care and patient recruitment: R. Hupperts. Manuscript drafting: L. Rolf and A.-H. Muris. Consultation for cardiology patient care: M. van Daele. Critical revision of the manuscript: J. Damoiseaux, M. van Daele, R. Hupperts.
Study funding: No targeted funding reported.
Disclosure: L. Rolf, A.-H. Muris, J. Damoiseaux, and M. van Daele report no disclosures. R. Hupperts received honoraria for lectures and advisory boards and Research Grants from Merck, Biogen Idec, Sanofi-Genzyme, Novartis, and TEVA.
- Received September 9, 2013.
- Accepted in final form December 2, 2013.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors
Dr. Josep Dalmau and Dr. Mar Guasp
► Watch
Topics Discussed
Alert Me
Recommended articles
Sphingosine 1-phosphate (S1P)
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis